

# Influenza Vaccine Product List and Age Groups --- United States, 2023-2024 Season<sup>1</sup>

*DoD contracted NH vaccines (highlighted green), SH vaccine (highlighted blue); \*DVD available vaccines (highlighted orange); Not available (not highlighted)*

Manufacturer	Trade Name (Vaccine abbreviation)	NDC	Presentation	Mercury (thimerosal) µg/0.5 mL	Ovalbumin mcg/0.5 mL	Age Group	CVX	CPT
Seqirus, Inc.	Afluria® <sup>1,2,3</sup> (IIV4)	33332-0323-03	0.5-mL PFS	0	< 1	3+ yr.	150	90686
		33332-0423-10	5-mL MDV <sup>2</sup> (0.25-mL dose for ages 6-35 mos.)	12.25	< 0.5	6+ mos.	158	90687
			5-mL MDV <sup>2</sup> (0.5-mL dose for ages 3+ yr.)	24.5	< 1			
	Fluad® <sup>1,5</sup> (aIIV4)	70461-0123-03	0.5-mL PFS	0	< 1	65+ yr.	205	90694
	Flucelvax® <sup>1</sup> (ccIIV4)	70461-0323-03	0.5-mL PFS	0	0	6+ mos.	171	90674
70461-0423-10		5-mL MDV	25	0	186		90756	
GlaxoSmithKline	Fluarix® <sup>1</sup> (IIV4)	58160-0909-52	0.5-mL PFS	0	≤ 0.05	6+ mos.	150	90686
ID Biomedical Corp (distributed by GlaxoSmithKline)	FluLaval® <sup>1</sup> (IIV4)	19515-0814-52	0.5-mL PFS	0	≤ 0.3	6+ mos.	150	90686
Sanofi Pasteur, Inc.	Fluzone® <sup>1,4</sup> (IIV4)	49281-0423-50	0.5-mL PFS	0	§§	6+ mos.	150	90686
		49281-0423-10	0.5-mL SDV	0	§§	6+ mos.	150	90686
		49281-0639-15	5-mL MDV <sup>4</sup> (0.25-mL or 0.5-mL dose for ages 6-35 mos.)	12.5/0.25 mL	§§	6+ mos.	158	90687
		49281-0639-15	5-mL MDV <sup>4</sup> (0.5-mL dose for ages 3+ yr.)	25/0.5 mL	§§			
	Fluzone® High-Dose <sup>1,6</sup> (HD-IIV4)	49281-0123-65	0.7-mL PFS	0	§§	65+ yr.	197	90662
	Fluzone® Southern Hemisphere <sup>1</sup> (SH-IIV4)	49281-0323-50	0.5-mL PFS	0	§§	6+ mos.	201	N/A
	FluBlok® <sup>1</sup> (RIV4)	49281-0723-10	0.5-mL PFS	0	0	18+ yr.	185	90682
AstraZeneca	FluMist® <sup>1</sup> (LAIV4)	66019-0310-10	0.2-mL prefilled single-use intranasal sprayer	0	≤ 0.024	2-49 yr.	149	90672

**Abbreviations:** DoD = Department of Defense; NH = Northern Hemisphere; SH = Southern Hemisphere; DVD = Direct Vendor Delivery; IIV4 = inactivated influenza vaccine, quadrivalent; aIIV4 = adjuvanted inactivated influenza vaccine, quadrivalent; ccIIV4 = cell culture-based vaccine, quadrivalent; RIV4 = recombinant influenza vaccine, quadrivalent; LAIV4 = live attenuated influenza vaccine, quadrivalent; PFS – prefilled syringes; MDV = multidose vial; SDV = single dose vial; FDA = Food and Drug Administration.

1. Vaccination providers should consult FDA-approved prescribing information for 2023-24 influenza vaccines for the most complete and updated information, including, but not limited to, indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at: <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states>. Availability and characteristics of specific products and presentations might change or differ from what is described in this table.

**2. Once the stopper of the Afluria® multidose vials are pierced the vial must be discarded within 28 days. The number of needle punctures should not exceed 20 per multidose vial.**

3. Afluria® is licensed for administration by needle and syringe (6 months and older) or by PharmaJet Stratis® Needle-Free Injection System (18 through 64 years).

4. The approved dose volume for Afluria Quadrivalent is 0.25-mL for children 6 through 35 months and a 0.5-mL dose for persons aged ≥3 years. However, 0.25-mL prefilled syringes are no longer available. For children aged 6 through 35 months, a 0.25-mL dose must be obtained from a multidose vial.

5. Fluzone® Quadrivalent is currently approved for ages 6 through 35 months as either 0.25-mL or 0.5-mL per dose; however, 0.25-mL prefilled syringes are no longer available. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this age group, the dose volume will be 0.5-mL per dose.

**6. No more than 10 doses (0.25-mL or 0.5-mL) should be withdrawn from the Fluzone® multidose vial.**

7. Fluad® includes the MF59C.1 adjuvant (MF59®), a squalene-based oil-in-water emulsion.

8. Quadrivalent inactivated vaccine high-dose: a 0.7-mL dose contains 60 µg of each vaccine antigen (180 µg total).

9. The Center for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) 2023-24 influenza season vaccine recommendations can be found at the following website:

<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html>

§§ Available upon request from Sanofi Pasteur (1-800-822-2463 or [MIS\\_emails@sanofipasteur.com](mailto:MIS_emails@sanofipasteur.com)).

\* DVD vaccines are available for purchase by MTFs. Refer to the Seasonal Influenza Program DHA-PI for information on the ordering process.